Golimumab (Simponi®) is a human immunoglobulin G1κ monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-α (TNFα). In 2009, it was approved by FDA for the trea™ent of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. BioVision’s Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. BioSim™ Golimumab ELISA kit has been developed for specific quantification of Golimumab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Golimumab in human serum and plasma.
•Detection range: 100 – 3000 ng/ml
• Sensitivity: 100 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
